Klotho Neurosciences, Inc. (KLTO)
2025-06-30 | ||||
|---|---|---|---|---|
| Income taxes | - | |||
| Share-based compensation | 390,195 | |||
| Research and development | 238,700 | |||
| Professional fees | 924,580 | |||
| General and administrative | 339,377 | |||
| Total operating expenses | 1,892,852 | |||
| Net operating loss | -1,892,852 | |||
| Other income (expense) | 12,668 | |||
| Interest expense | 1,760,025 | |||
| Loss on conversion of debt | -331,546 | |||
| Change in fair value of warrant liability | 121,476 | |||
| Total other income (expense) | -2,200,379 | |||
| Net loss before income taxes | -4,093,231 | |||
| Net loss | -4,093,231 | |||
| Net loss per share basic (in dollars per share) | -0.12 | |||
| Net loss per share diluted (in dollars per share) | -0.12 | |||
| Weighted average common shares outstanding (in shares) | 33,952,418 | |||
| Weighted-average common shares outstanding, diluted | 33,952,418 | |||